CN109781984A - A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers - Google Patents
A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers Download PDFInfo
- Publication number
- CN109781984A CN109781984A CN201910086988.0A CN201910086988A CN109781984A CN 109781984 A CN109781984 A CN 109781984A CN 201910086988 A CN201910086988 A CN 201910086988A CN 109781984 A CN109781984 A CN 109781984A
- Authority
- CN
- China
- Prior art keywords
- antibody
- liver cancer
- marker
- markers
- antibody chip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses the antibody chip kits that a kind of simultaneous quantitative detects multiple liver cancer markers.Present invention research has found one group of marker combination that can be combined for hepatocarcinoma early diagnosis: B2M, IGFBP3, GP73, GDF-15, OPN, AFP, it is very suitable for the early diagnosis of liver cancer, improve the sensibility and specificity of diagnosing cancer of liver, the diagnosis, treatment or prognostic evaluation that can be used for liver cancer, improve the survival rate of liver cancer patient.It is combined the present invention is based on the marker and kit is constructed using antibody combined detection chip technology; 6 kinds of tumor markers of above-mentioned marker combination need to only be detected; extraordinary detection effect can be reached; the blank of antibody chip detection early liver cancer is not only filled up; and overcome that prior art operation is cumbersome, Testing index is single, need to have the defects such as expense instrument, sensitivity is low, have many advantages, such as that cheap, convenient, sensitive, accurate, high-throughput, sample dosage is few, can be in common lab popularization and scale.
Description
Technical field
The invention belongs to field of biomedicine technology.Multiple liver cancer marks are detected more particularly, to a kind of simultaneous quantitative
The antibody chip kit of object.
Background technique
Liver cancer is clinically one of most common malignant tumour, occupies the 3rd of tumour associated death.Currently, China is sent out
Patient's number accounts for about the 55% of the whole world；It is only second to lung cancer in tumour associated death, occupies second.Therefore, liver cancer seriously threatens me
State's people's health and lives.Liver is the maximum parenchymatous organ of human body, undertakes all kinds of important metabolic functions of human body, therefore,
Malignant tumour, which once occurs, in liver not will lead to not and the serious consequence of life.Again since liver has supply of blood flow abundant, with
The important feature of human body such as inferior caval vein, portal vein, biliary system etc. is in close relations；Liver malignancy incidence of occult, invasion
Property fast growing, treatment is very difficult.Therefore, early detection, early diagnosis are to the treatment of liver cancer and its important.
Currently, the early diagnosis of liver cancer relies primarily on blood serum tumor markers detection, early stage liver cancer patient, in serum
There are several molecular levels to have occurred that apparent variation, can be used as by the quantitative check to these molecular levels in serum
One effective means of liver cancer prediction.The early detection rate of liver cancer is low at present, mainly with the symptom of early liver cancer it is unobvious and
It is related to lack effective detection means currently on the market.At present clinically for the method that detects liver cancer include Imaging Method such as
PET-CT, pathological biopsy are verified.PET-CT inspection fee is expensive, and invasive biopsy is extremely painful for patient.
Therefore, it is necessary to develop the immunity detection reagent that can detect early liver cancer.
Currently, the detection method of common tumor markers specifically includes that enzyme linked immunosorbent assay (ELISA), radiation is exempted from
Epidemic disease analyzes (radio immunoassay, RIA), Diagnosis of Sghistosomiasis achievement method (western blot), flow cytometer (Flow-
Cytometry) etc..Wherein, enzyme linked immunosorbent assay is most common method, and tool high sensitivity, specificity are preferable, easy to operate
The advantages that.But primary test can only detect single index, and flux is low, at high cost, in the detection of multi-tumor marker, this method
There are clearly disadvantageous；Radiommunoassay (RIA) is due to radioactive pollution, seldom now although high sensitivity
Using；Diagnosis of Sghistosomiasis achievement method can measure bulk of molecule, and without non-specific reaction, but cumbersome, and sensitivity is low, and can only examine
Survey single index；Flow cytometer can detect the level of tumor markers on a cellular level, but there are low sensitive, low passes
The disadvantages of amount, Gao Chengben, and the device structure used in the method is complicated, is not easy to promote.
Summary of the invention
The technical problem to be solved by the present invention is to overcome the defects and deficiency of existing liver cancer early detection diagnostic techniques, provide
A kind of combined detection kit of high-throughput, highly sensitive, high specific and the multi-tumor marker of low cost.Using antibody core
Chip technology detects 6 markers combination of early liver cancer, overcomes that prior art operation is cumbersome, Testing index is single, need to have expense
The defects such as instrument, sensitivity is low, have that cheap, convenient, sensitive, accurate, high-throughput, sample dosage is few, can be in common lab
The advantages that popularization and scale.
The object of the present invention is to provide a kind of marker combinations for liver cancer early detection.
Another object of the present invention provides the antibody chip kit that a kind of simultaneous quantitative detects multiple liver cancer markers.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
A kind of marker combination for liver cancer early detection, including following 6 clock marker: B2M (β2-microglobulin),
IGFBP3 (insulin-like growth factor binding protein 3), GP73 (golgiosome 73), GDF-15 (growth differentiation factor-15),
OPN (osteopontin), AFP (alpha-fetoprotein).
A kind of marker specific antibody combination for liver cancer early detection, the specificity including following 6 clock marker
Antibody: B2M, IGFBP3, GP73, GDF-15, OPN, AFP.
The marker combination or marker specific antibody combination are in the antibody chip reagent for preparing diagnosing cancer of liver
Application in terms of box, also within protection scope of the present invention.
A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers, including specific antibody: being selected from needle
To the antibody of following liver cancer marker: B2M, IGFBP3, GP73, GDF-15, OPN, AFP.
Preferably, the antibody chip kit further includes solid phase carrier: using the coated normal structure slide of active amino；
The specific antibody is individually fixed on the solid phase carrier, forms several independent recognition sites.
It is highly preferred that the antibody chip kit also comprises the following components:
Reactant and detection agent: including antibody mixed liquor, the antibody mixed liquor is several strain specific antibodies
Mixed solution, marking on the specific antibody in antibody mixed liquor has；
Streptavidin: the biotin labeling on specific antibody for identification；The marked by streptavidin has fluorescence
Dyestuff, the fluorescent dye are Cy3 or the fluorescent dye with similar absorbing wavelength；
Tumor markers standard items: for the mixture of the several tumor markers with step concentration.
Preferably, the tumor markers standard items include: 200000pg/ml IGFBP-3,10000pg/mlB2M,
10000pg/ml GP73,2000pg/ml GDF-15,1000000pg/ml OPN, 10000pg/mlAFP.
Preferably, the antibody chip kit further includes reference substance: including control serum and making a definite diagnosis In Sera of Patients With Hepatocarcinoma.
The construction method of antibody chip in mentioned reagent box are as follows: a surface of glass slide will be a variety of with untouchable point sample instrument
Antigen-specific antibodies point by way of microarray has 2 × 8 identical Antibody microarrays, and point is had 2 × 8 micro- battle arrays of antibody
Slide is divided into 16 non-interfering cells, Mei Ge little with removable 2 × 8 hole frame structure by the normal structure slide of column
Contain an Antibody microarray in area；Antibody chip is formed by the frame clamping buckle of two sides between slide and frame.
Quantitative detection multiple liver cancer marks while the marker of hepatocarcinoma early diagnosis of the invention is combined and constructed based on this
The antibody chip kit of will object is very suitable for early diagnosing liver cancer, has cheap, convenient, sensitive, accurate, high-throughput, mark
This dosage is few, can promote in common lab and the advantages that scale, can be used for the diagnosis of liver cancer, especially early diagnose, with
And in terms of liver cancer treatment and prognostic evaluation.
The invention has the following advantages:
The present invention have found one group can combine for hepatocarcinoma early diagnosis marker combination, be B2M, IGFBP3,
This 6 kinds of markers of GP73, GDF-15, OPN, AFP are to screen from 274 kinds of markers by the innovative approach of inventor
, detection system is close to be can be realized while detecting, and is very suitable for early diagnosing liver cancer, the antibody combination of this 6 kinds of markers
It is to report for the first time, detection effect is high specific and high sensitivity.It can be used for the diagnosis, treatment or prognostic evaluation of liver cancer,
The sensibility and specificity for improving diagnosing cancer of liver improves the survival rate of liver cancer patient.
The present invention constructs kit using antibody combined detection chip technology simultaneously, and it is early not only to have filled up antibody chip detection
The blank of phase liver cancer, and overcome that prior art operation is cumbersome, Testing index is single, need to have expense instrument, sensitivity are low etc. to lack
It falls into, with cheap, convenient, sensitive, accurate, high-throughput, sample dosage is few, can be excellent in common lab popularization and scale etc.
Point.It can be used for mass survey, be conducive to establish Baseline Data.Especially for the early detection diagnosis of liver cancer, treat in time, it will
Cure rate is greatly improved, medical expense is lowered.In the diagnosis of liver cancer, especially early diagnoses and liver cancer treatment and prognosis are commented
In terms of valence, all have a good application prospect.
Detailed description of the invention
Fig. 1 is the screening process figure of liver cancer marker in embodiment 1；
Fig. 2 is the ROC curve figure of 17 kinds of factors of training group in embodiment 1；
Fig. 3 is the cross validation schematic diagram of 17 kinds of factors in embodiment 1；
Fig. 4 is the ROC curve figure of 6 kinds of factors of training group in embodiment 1；
Fig. 5 is the cross validation schematic diagram of 6 kinds of factors in embodiment 1；
Fig. 6 be in embodiment 2 reversed protein chip detect respectively β2-microglobulin, IGFBP3 albumen, GP73 albumen,
The result scanning figure of GDF15 albumen, OPN albumen and AFP albumen；
Fig. 7 be embodiment 2 hepatoma sample and healthy sample in β2-microglobulin, IGFBP3 albumen, GP73 albumen,
GDF15 albumen, OPN albumen and AFP protein content comparison diagram.
Specific embodiment
The present invention is further illustrated below in conjunction with Figure of description and specific embodiment, but embodiment is not to the present invention
It limits in any form.Unless stated otherwise, the present invention uses reagent, method and apparatus routinely try for the art
Agent, method and apparatus.
Unless stated otherwise, following embodiment agents useful for same and material are commercially available.
Embodiment 1 is used to detect the determination of the serum markers of early liver cancer
The experiment volunteer of the present embodiment includes cancer patient, other cancer patients and healthy population, liver cancer marker
Screening process is shown referring to Fig.1.Based on ELISA method, the blood serum sample provided from experiment volunteer is provided and is coated with
For the antibody chip of the antibody of 274 serum markers, artificial neural network analysis is carried out to antibody chip testing result.If
78 liver cancer samples, 40 other cancer samples and 80 healthy samples are set, normalizing is carried out to the data that antibody chip provides
Change processing.The standard items curve that target elements are obtained using relevant criterion product, according to standard items curve determination protein concentration.Thus
It was found that there is 21 kinds of factors to be obviously different from the content in other cancer samples and healthy sample in the content in liver cancer sample.
According to the requirement of value < 0.01 P, 17 kinds of factors that therefrom selection meets the requirement carry out statistical modeling.This 17 factors are AFP,
GDF15,CEACAM1,MMP9,GP73,B2M,IGFBP3,ACRP30,Ferritin,Axl,LYVE-1,Fas,DKK-1,HGF,
IL8,FGF9,Nidogen1.17 factors that Integrated Selection goes out, are respectively adopted logistic regression (LR), linear discriminant analysis
(LDA), the sensitivity of the factor is chosen in random forest (RF) and the evaluation of 4 group model of support vector machines (SVM), specificity and accurate
Rate.
The present embodiment uses and stays a cross validation screening technique (leave-one-out cross-validation
Approach): sample N is divided into training group N-1 and prediction group 1 by every bout, will obtain N number of model, final with N number of model
Prediction group classification accuracy performance indicator of the average as this lower classification samples.The advantages of this screening technique is each
Almost all of sample is all used for training pattern in bout, therefore closest to the distribution of original sample, assesses resulting knot in this way
Fruit is reliable；There is no enchancement factor to will affect experimental data in experimentation, it is ensured that experimentation can be replicated.From
Training group obtains model, then is verified using prediction group.It is acquired as can be seen from Figure 2 according to above-mentioned 4 kinds of models about training
For area under Receiver operating curve's (ROC curve) of 17 kinds of factors of group close to 1, accuracy rate is high.We continue to reduce
The factor quantity of model is tested, and from 16 kinds of factors to 2 kinds of factors, observes β2-microglobulin, IGFBP3 albumen, GP73 egg
White, GDF15 albumen, the accuracy rate of OPN albumen and AFP albumen this 6 kinds of factors are suitable with 17 kinds of factors, the ROC curve of 6 kinds of factors
The accuracy and KAPPA value such as Fig. 3,5 of area under (as shown in Figure 4) also close to 1,17 kind of factor and 6 kinds of factor cross validations
It is shown.The data that Tables 1 and 2 provides are compared, sensitivity, specificity and the accuracy in table illustrate test sample all very close to 1
Testing result of 17 kinds of factors and 6 kinds of factors can correctly identify the patient and non-patient for distinguishing liver cancer in this, accordingly to reality
The diagnosis reliability with higher of the person's of testing progress liver cancer state.
The Performance Evaluation of 1 17 kinds of factor models of table
The Performance Evaluation of 26 kinds of factor models of table
Embodiment 2 verifies 6 antibody using reversed protein chip
The operating procedure of reversed protein chip is as follows:
Sample treatment: the blood serum sample that experimenter provides is handled using appropriate buffer and serial dilution.
Standard items preparation: it is 100g/ml (stoste) that 6 factor recombinant proteins, which are configured to concentration, according to each factor mark
The initial concentration of directrix curve dilutes 5 times according to different 1/3 multiples, and blank control is arranged.
Diaphragm preparation: by diluted blood serum sample, standard items, positive control and blank control point sample to diaphragm.800cw-
Streptavidin contains the PBS buffer solution of 1%BSA as negative control as sun control.It is after point sample, diaphragm is naturally dry
It is dry and be stored in -80 DEG C.Diaphragm detection: slide is balanced to room temperature, is incubated for 30 minutes with Block buffer；Biotin is added
Labelled antibody solution is incubated for 2 hours；1 × 800cw-conjugated streptavidin is added and (uses blockingbuffer
8000 times of dilution), it is incubated at room temperature 2h；It is scanned at 532nm after washing by Genepix 4000B laser scanner.
It is scanned using ImageQuant LAS4000 chemiluminescence imaging analysis system
1) scanner: ImageQuant LAS4000Scanner
2) brand: GE company, the U.S. (GE Healthcare Corporate)
3) place of production: USA
4) sweep parameter: high resolution
Data are extracted using the included analysis software of instrument, software is analyzed using IBM SPSS to carry out data analysis.
By data analysis such as Fig. 6, learn that 6 factors have significant difference (P < 0.05).
In addition the β2-microglobulin in hepatoma sample and healthy sample, IGFBP3 albumen, GP73 albumen, GDF15 albumen,
OPN albumen and AFP protein content comparison diagram such as Fig. 7.
The antibody chip kit of a liver cancer marker of embodiment more than 3
A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers, including following component:
Specific antibody: selected from be directed to following liver cancer marker antibody: B2M, IGFBP3, GP73, GDF-15, OPN,
AFP；
Solid phase carrier: the coated normal structure slide of active amino is used；
The specific antibody is individually fixed on the solid phase carrier, forms several independent recognition sites.
Reactant and detection agent: including antibody mixed liquor, the antibody mixed liquor is several strain specific antibodies
Mixed solution, marking on the specific antibody in antibody mixed liquor has；
Streptavidin: the biotin labeling on specific antibody for identification；The marked by streptavidin has fluorescence
Dyestuff, the fluorescent dye are Cy3 or the fluorescent dye with similar absorbing wavelength；
Tumor markers standard items: for the mixture of the several tumor markers with step concentration；
Specifically, the tumor markers standard items are as follows:
Further include reference substance: including control serum and making a definite diagnosis In Sera of Patients With Hepatocarcinoma.
The construction method of mentioned reagent box are as follows: in a surface of glass slide with untouchable point sample instrument by a variety of antigentic specificities
Antibody point by way of microarray has 2 × 8 identical Antibody microarrays, and point is had to the standard group of 2 × 8 Antibody microarrays
It knits slide and slide is divided into 16 non-interfering cells with removable 2 × 8 hole frame structure, each cell contains one
Antibody microarray；Antibody chip is formed by the frame clamping buckle of two sides between slide and frame.
The experiment of the kit quantification detection tumor markers of the invention of embodiment 4
1, slide chip is completely dried
Slide chip is taken out from box, after 20~30min of equilibrium at room temperature, packaging bag is opened, opens sealing
Then chip is placed on vacuum desiccator or drying at room temperature 1~2 hour by item.
2, gradient dilution is carried out to tumor markers standard items gradient
(1) sample diluting liquid of 500 μ l is added into the tubule of tumor markers correct mixture, re-dissolves standard
Product.Before opening tubule, first quickly centrifugation, gently upper and lower lash dissolved powders, and marking this tubule is Std 1.
(2) 6 clean centrifuge tubes of label are Std2, Std3 to Std7 respectively, add the sample diluting liquid of 200 μ l to often
In a tubule.
(3) Std 1 for extracting 100 μ l, which is added in Std2, to be gently mixed, and 100 μ l are then extracted from Std 2 and are added to
In Std 3, such gradient dilution to Std7.
(4) sample diluting liquid of 100 μ l is extracted into another new centrifuge tube, is labeled as CNTRL, as negative right
According to.
Note: because the initial concentration of every kind of tumor markers is different, after the gradient dilution of Std1 to Std7, often
The series of concentrations of a tumor markers is different.
3, chip operation process
(1) sample diluting liquid of each 100 μ l of Kong Zhongjia is incubated for 30 minutes on room temperature shaker, closes quantitative antibody chip.
(2) buffer in each hole is pumped, the titer and sample for adding 100 μ l are stayed overnight for 4 DEG C on shaking table into hole
It is incubated for.Sample is the serum being precipitated naturally after venous blood collection, is diluted using preceding with sample dilution 1:1；
(3) it cleans
The standard items or sample in each hole are pumped, 1 × washing lotion I is cleaned 5 times, each 5min room temperature shaker concussion, every hole
1 × washing lotion I of 150 μ l, cleaning will be cleaned washing lotion every time, dilute 20 × washing lotion I with deionized water.
1 × washing lotion I in each hole is pumped, 1 × washing lotion II is added and cleans 2 times, each 5min room temperature shaker concussion, every hole
1 × washing lotion II of 150 μ l, cleaning will be cleaned washing lotion every time, dilute 20 × washing lotion II with deionized water.
(4) incubation of antibody mixture is detected
Centrifugation detection antibody mixture tubule, then be added 1.4ml sample diluting liquid, after mixing again quickly from
The heart.The detection antibody of 80 μ l is added into each hole, is incubated for 2 hours on room temperature shaker.
(5) it cleans
The detection antibody in each hole is pumped, 1 × washing lotion I is cleaned 5 times, each 5min room temperature shaker concussion, every 150 μ l of hole
1 × washing lotion I, cleaning will be cleaned washing lotion every time, 1 × washing lotion II is then added and cleans 2 times, the shake of each 5min room temperature shaker
It swings, 1 × washing lotion II of every 150 μ l of hole, cleaning will be cleaned washing lotion every time.
(6) incubation of Cy3- Streptavidin
Be centrifuged Cy3- Streptavidin tubule, then be added 1.4ml sample diluting liquid, after mixing again quickly from
The heart.The Cy3- Streptavidin of 80 μ l is added into each hole, slide is encased with aluminium-foil paper and is protected from light incubation, be incubated on room temperature shaker
1 hour.
(7) it cleans
The Cy3- Streptavidin in each hole is pumped, 1 × washing lotion I is cleaned 5 times, each 5min room temperature shaker concussion, often
1 × washing lotion I of 150 μ l of hole, cleaning will be cleaned washing lotion every time.
(8) fluorescence detection
1) slide frame is dismantled, does not touch the one side of slide printing antibody with hand carefully.
2) slide is placed in glass slide cleaning pipe, adds 1 × washing lotion I of about 30ml, slide can be entirely covered, in room
15min is shaken on warm shaking table, discards 1 × washing lotion I, 1 × washing lotion II of about 30ml is added, 5min is shaken on room temperature shaker.
3) the residual washing lotion of slide is removed.Slide is placed in glass slide cleaning pipe/drying tube, not lid lid,
1000rpm is centrifuged 3min.
4) laser scanner such as Axon GenePix scanning signal is used, using Cy3 or green channel (stimulating frequency
=532nm).
(9) data of chip are extracted and carry out data analysis with analysis software.
1) fluorescent value of biochip is read with GenePix software.6 (row) x 8 (column) of the microarray parameter of chip,
The diameter 120um of point.
2) numerical value selected after reading is the median reading (F532Median-Local for removing local background
Background)。
4, result
T in order to detect the protein expression difference in cancer and check sample, after being corrected using SSPS statistical software
Check analysis.For further sort research, the statistical significance threshold value of each marker is set as P < 0.05.Normal distribution
It is analyzed with Kolmogorov-Smirnove test and Shapiro-Wilk test (SSPS statistical software).Normal distribution quilt
It is set to P > 0.05.Highly relevant marker on antibody chip is screened for hierarchical cluster analysis.Regression analysis is used for
Examine the correlation and conspicuousness of antibody chip and other methods (Western blot and ELISA) resulting data.Express water
The flat T check analysis for being used for correction plus the albumen of 2xSD higher than background.In order to analyze whether sample meets normal distribution, Ke Er
Brother's love-Vladimir Smirnov (Kolmogorov-Smirnova) is not examined and Xia Piluo-Weir gram (Shapiro-Wilk) is examined
It is used to analysis cancer group and control group.According to the results show that this kit can be detected in early liver cancer serum sample it is different
Chang Zhibiao is increased, and can be distinguished with other tumours, specificity with higher.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present invention,
It should be equivalent substitute mode, be included within the scope of the present invention.
Claims (9)
1. a kind of marker for liver cancer early detection combines, which is characterized in that including following 6 kinds of markers: B2M,
IGFBP3、GP73、GDF-15、OPN、AFP。
2. a kind of marker specific antibody for liver cancer early detection combines, which is characterized in that including following 6 kinds of markers
Specific antibody: B2M, IGFBP3, GP73, GDF-15, OPN, AFP.
3. marker specific antibody combination described in the combination of marker described in claim 1 or claim 2 is examined in preparation liver cancer
Application in terms of disconnected antibody chip kit.
4. the antibody chip kit that a kind of simultaneous quantitative detects multiple liver cancer markers, which is characterized in that anti-including specificity
Body: selected from the antibody for being directed to following liver cancer marker: B2M, IGFBP3, GP73, GDF-15, OPN, AFP.
5. antibody chip kit according to claim 4, which is characterized in that further include solid phase carrier；The solid phase carries
Body is with the coated normal structure slide of active amino；The specific antibody is individually fixed on the solid phase carrier, is formed
Several independent recognition sites.
6. antibody chip kit according to claim 4 or 5, which is characterized in that also comprise the following components:
Reactant and detection agent: including antibody mixed liquor；The antibody mixed liquor is the mixing of several strain specific antibodies
Solution, marking on the specific antibody in antibody mixed liquor has；
Streptavidin: the marked by streptavidin has fluorescent dye, and the fluorescent dye is Cy3 or has similar absorption wave
Long fluorescent dye；
Tumor markers standard items: the mixture of several tumor markers.
7. antibody chip kit according to claim 6, which is characterized in that further include reference substance: including control serum
With make a definite diagnosis In Sera of Patients With Hepatocarcinoma.
8. antibody chip kit according to claim 6, which is characterized in that the tumor markers standard items include:
200000pg/ml IGFBP-3,10000pg/ml B2M, 10000pg/ml GP73,2000pg/ml GDF-15,
1000000pg/ml OPN, 10000pg/ml AFP.
9. according to any antibody chip kit of claim 4~8, which is characterized in that the construction method of antibody chip
Are as follows: in a surface of glass slide, with untouchable point sample instrument, by a variety of antigen-specific antibodies, the point by way of microarray has 2 × 8
Point is had the normal structure slide of 2 × 8 Antibody microarrays with removable 2 × 8 hole frame knot by a identical Antibody microarray
Slide is divided into 16 non-interfering cells by structure, and each cell contains an Antibody microarray；Lead between slide and frame
The frame clamping buckle for crossing two sides forms antibody chip.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910086988.0A CN109781984A (en) | 2019-01-29 | 2019-01-29 | A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910086988.0A CN109781984A (en) | 2019-01-29 | 2019-01-29 | A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109781984A true CN109781984A (en) | 2019-05-21 |
Family
ID=66503619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910086988.0A Pending CN109781984A (en) | 2019-01-29 | 2019-01-29 | A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109781984A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111537710A (en) * | 2020-03-30 | 2020-08-14 | 广州瑞博奥生物科技有限公司 | Marker combination, antibody chip and kit for detecting hand-foot-and-mouth disease |
| CN111638364A (en) * | 2020-04-30 | 2020-09-08 | 吉林省格瑞斯特生物技术有限公司 | GDF15 rapid quantitative fluorescent microsphere detection device and preparation method thereof |
| CN114292917A (en) * | 2021-12-31 | 2022-04-08 | 中国人民解放军空军军医大学 | Liver cancer prognosis risk model based on m6A characteristic gene and application thereof |
| WO2023008427A1 (en) * | 2021-07-26 | 2023-02-02 | 国立大学法人大阪大学 | Diagnostic marker for hepatic cancer development in chronic hepatic disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104215761A (en) * | 2014-08-27 | 2014-12-17 | 广西医科大学 | Kit for detecting anti-GP73 antibody in serum |
| CN105572353A (en) * | 2014-10-17 | 2016-05-11 | 广州瑞博奥生物科技有限公司 | Antibody chip reagent kit for detecting hepatoma marker |
| CN109212192A (en) * | 2018-09-30 | 2019-01-15 | 郑州安图生物工程股份有限公司 | GP73 detection kit for primary carcinoma of liver early diagnosis |
-
2019
- 2019-01-29 CN CN201910086988.0A patent/CN109781984A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104215761A (en) * | 2014-08-27 | 2014-12-17 | 广西医科大学 | Kit for detecting anti-GP73 antibody in serum |
| CN105572353A (en) * | 2014-10-17 | 2016-05-11 | 广州瑞博奥生物科技有限公司 | Antibody chip reagent kit for detecting hepatoma marker |
| CN109212192A (en) * | 2018-09-30 | 2019-01-15 | 郑州安图生物工程股份有限公司 | GP73 detection kit for primary carcinoma of liver early diagnosis |
Non-Patent Citations (6)
| Title |
|---|
| LIANG WANG等: "Growth differentiation factor 15 promotes cell viability, invasion, migration, and angiogenesis in human liver carcinoma cell line HepG2", 《CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY》 * |
| 吴寒等: "骨桥蛋白在肝细胞癌诊治中的作用", 《临床肝胆病杂志》 * |
| 姜丹丹: "血清β2-微球蛋白检测对原发性肝癌临床应用价值的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 温旺荣等: "《临床分子诊断学》", 31 March 2014, 广东科技出版社 * |
| 王天宝等: "《实用胃肠恶性肿瘤诊疗学 上 volume 1 普及版》", 31 July 2018, 广东科技出版社 * |
| 罗开忠等: "原发性肝癌患者血清 IGFBP-3浓度的测定及临床意义", 《中国医师杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111537710A (en) * | 2020-03-30 | 2020-08-14 | 广州瑞博奥生物科技有限公司 | Marker combination, antibody chip and kit for detecting hand-foot-and-mouth disease |
| CN111638364A (en) * | 2020-04-30 | 2020-09-08 | 吉林省格瑞斯特生物技术有限公司 | GDF15 rapid quantitative fluorescent microsphere detection device and preparation method thereof |
| WO2023008427A1 (en) * | 2021-07-26 | 2023-02-02 | 国立大学法人大阪大学 | Diagnostic marker for hepatic cancer development in chronic hepatic disease |
| CN114292917A (en) * | 2021-12-31 | 2022-04-08 | 中国人民解放军空军军医大学 | Liver cancer prognosis risk model based on m6A characteristic gene and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109781984A (en) | A kind of simultaneous quantitative detects the antibody chip kit of multiple liver cancer markers | |
| CN103869068B (en) | A kind of antibody chip kit for kinds of tumors diagnosis | |
| CN105572353B (en) | A kind of antibody chip kit for detecting liver cancer marker | |
| CN102209968B (en) | The capturing agent of lung cancer biomarkers albumen is in the purposes of preparing in kit | |
| KR100679173B1 (en) | Protein markers for diagnosing stomach cancer and the diagnostic kit using them | |
| CN102625915A (en) | Method for measurement of glycoprotein, method for detection of hepatic diseases, reagent for quantification of glycoprotein, and sugar chain marker glycoprotein as measure of disease conditions of hepatic diseases | |
| CN106248940B (en) | The system of multi objective Combining diagnosis oophoroma and/or the malignant tumour of non-ovary origin | |
| CN107407682A (en) | Differentiate the ill method of liver disease | |
| CN105572354A (en) | Antibody chip kit for detecting early gastric cancer | |
| CN108956968A (en) | The method for diagnosing proliferative disorders | |
| CN107102142A (en) | Detect protein markers/mark of gland cancer | |
| CN103038642B (en) | Method, array and use thereof | |
| CN106771248B (en) | High-level serous ovarian cancer diagnosis and/or the marker of Index for diagnosis | |
| CN104422768A (en) | Antibody chip kit for joint detection of early ovarian cancer markers | |
| CN105092844A (en) | Pancreatic cancer protein biomarker detection kit and detection system | |
| CN101587125B (en) | High expression cancer marker and low expression tissue organ marker kit | |
| CN110196329A (en) | A kind of cancer of the esophagus early stage combined detection kit | |
| CN106546744A (en) | By the method and corresponding reagent box of fecal hemoglobin, transferrins and PKM2 joint-detection assessing colorectal cancers | |
| CN105092845A (en) | Pancreatic cancer protein biomarker and application and detection chip thereof, and detection device | |
| CN104380112B (en) | Maternal biomarkers for gestational diabetes | |
| CN106680515B (en) | It is combined for the polymolecular marker of pulmonary cancer diagnosis | |
| WO2024001044A1 (en) | Biomarker combination related to lung cancer, kit containing same, and use thereof | |
| CN113702637B (en) | Lectin test carrier, kit and prediction model for predicting neoadjuvant chemotherapy curative effect of breast cancer | |
| CN101963618B (en) | Method for identifying heterophilic antibody interference in antibody microarray system and antibody microarray chip using same for detecting target antigen | |
| CN109085359A (en) | Serum protein markers combine the application in colorectal cancer screening and diagnosis and treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 510530 No. 79 Ruihe Road, Science City, Guangzhou High-tech Industrial Development Zone, Guangdong Province Applicant after: Reboo (Guangzhou) Biotechnology Co.,Ltd. Applicant after: SOUTH CHINA BIOCHIP RESEARCH CENTER IN GUANGZHOU Address before: No. 79, Ruihe Road, Science City, high tech Industrial Development Zone, Huangpu District, Guangzhou City, Guangdong Province, 510530 Applicant before: RAYBIOTECH Inc. GUANGZHOU Applicant before: SOUTH CHINA BIOCHIP RESEARCH CENTER IN GUANGZHOU |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190521 |
|
| RJ01 | Rejection of invention patent application after publication |